DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07629401

Unknown

Provide Pre-approval Expanded Access of LY3437943

Provide Pre-approval Expanded Access of Retatrutide

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

0

Recruiting sites

—

Enrollment

—

Study population

—

Key I/E criterion

—

Primary endpoint

—

Identifiers

Registered as

NCT IDNCT07629401
Org study ID27979
Secondary IDJ1I-MC-Y001Eli Lilly and Company

Timeline

Milestones

Study first posted2026-06-05actual
Last update posted2026-06-05actual

Assets

Investigational agents

Retatrutide

Eligibility

Who can enroll

Inclusion criteria

Exclusion criteria

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.